Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2020 | TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer | Oxnard G.R.; CHIH-HSIN YANG ; Yu H.; Kim S.-W.; Saka H.; Horn L.; Goto K.; Ohe Y.; Mann H.; Thress K.S.; Frigault M.M.; Vishwanathan K.; Ghiorghiu D.; Ramalingam S.S.; Ahn M.-J. | Annals of Oncology | 282 | 228 |